Travere Therapeutics, Inc.
TVTX· Nasdaq
TVTXTravere Therapeutics, Inc.
Filed Feb 19, 2026 · 10-K · 50 days after period end · 0001438533-26-000014
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023 | Q4 2022 |
|---|---|---|---|---|
| Revenue | $129.69M | $74.79M | $45.06M | $29.34M |
| Net Income | $2.73M | -$60.26M | -$90.17M | -$65.82M |
| EPS Diluted | — | — | -$1.18 | -$1.03 |
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2025 · filed Feb 19, 2026 · 50 d after period end
